A Follow-up Study of Immune Dysregulation in Patients With COVID-19
Study Details
Study Description
Brief Summary
In order to detect the immunosuppression status of COVID-19 patients, this study collected blood samples of COVID-19 patients on the 10th, 20th and 30th days after the onset of symptoms, and detected the proinflammatory, anti-inflammatory factors，immunosuppressive marker，immune cells in the blood samples to evaluate the immunosuppression status of COVID-19 patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
After SARS-CoV-2 infection, the patient's immune system is overactivated. While the immune cells release a large number of proinflammatory factors, anti-inflammatory response starts at the same time. Anti-inflammatory factors such as IL-4, IL-10, and IL-37 will be compensated to resist the release of proinflammatory factors and prevent the further development of systemic inflammatory response. However, when the anti-inflammatory factor is excessively released, it will cause compensatory response syndrome, leading to immunosuppression. Whether the level of anti-inflammatory factors continues to rise, and whether it will lead to the persistence of later immunosuppression is unknown. Therefore, this study intends to recruit COVID-19 patients, detect the pro-inflammatory and anti-inflammatory factors，immunosuppressive marker，immune cells in 10 days, 17days, and 24days after the symptoms appear, and evaluate the immunosuppression status of patients with COVID-19
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| mid covid-19 patients Participant is diagnosed with symptomatic COVID-19 by a positive PCR for SARS-CoV-2 or antigen quicktest and meet the standard of mild COVID-19 |
Diagnostic Test: mid covid-19 patients
Collect the patient's whole blood for testing
|
Outcome Measures
Primary Outcome Measures
- The concentration of inflammatory markers (IL-1β、IL-2、 IL-2R 、IL-4 、 IL-6 、 IL-8、 IL-10 、IFN-γ、TNF-α 、VEGF, etc.) in peripheral blood. [10, 20, 30days]
- The concentration of immunosuppression makers(HLA-DR, PD-1, TIM-3,etc.) in peripheral blood. [10, 20, 30days]
- The number of immune cells(Th1/Th2 cell, Treg cell, MDSCs,etc.) in peripheral blood. [10, 20, 30days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant is diagnosed with symptomatic COVID-19 by a positive PCR for SARS-CoV-2 or antigen quicktest.
-
Study participant is 18 years of age or older
Exclusion Criteria:
-
Patients with immunosuppression, including HIV infection, hematopoietic stem cell transplantation and high-dose immunosuppressant therapy
-
Pregnancy or breastfeeding
-
Patients receiving chemotherapy or other cancer treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Qilu Hospital of Shandong University | Jinan | Shandong | China | 250012 |
Sponsors and Collaborators
- Qilu Hospital of Shandong University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Qilu-20221224-pang